Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nivagen Pharmaceuticals Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 2 distinct examiners, which shows that one examiner is handling more than one matter for the company. The prosecution is taking place within 2 distinct art units, indicating some technical variety in the pharmaceutical applications being pursued.
ROGERS, JAMES WILLIAM is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. Since there are only 3 pending office actions total, the 2 pending office actions under ROGERS, JAMES WILLIAM represent the primary focus of the current workload. This makes the interaction with this specific examiner a critical factor for the company's success in the Biotechnology & Pharmaceuticals sector.
With 2 distinct examiners and 2 distinct art units, the portfolio is relatively compact but requires attention to the specific requirements of each unit. The fact that ROGERS, JAMES WILLIAM manages 2 pending office actions suggests that a consistent strategy can be applied to those specific matters. Practitioners should focus on the 3 pending office actions to ensure the 2 distinct examiners receive clear and persuasive arguments.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, JAMES WILLIAM | 2 | 46.2% | +22.3% |
| RAMOS LEWIS, JOSMALEN MILAGROS | 1 | 53.6% | +23.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19249060 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | ROGERS, JAMES WILLIAM | 60d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18594178 | Chlorthalidone Compositions And Methods | RAMOS LEWIS, JOSMALEN MILAGROS | 40d |
| 19249060 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | ROGERS, JAMES WILLIAM | 60d |
| 19249149 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | ROGERS, JAMES WILLIAM | 60d |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19249060 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | ROGERS, JAMES WILLIAM | 1618 | §102§103 | Non-Final OA | 60d | Pending | Jun 25, 2025 |
| 19249149 | STABLE INTRAVENOUS DILTIAZEM HYDROCHLORIDE FORMULATION AND USE THEREOF | ROGERS, JAMES WILLIAM | 1618 | §103 | Non-Final OA | 60d | Pending | Jun 25, 2025 |
| 18594178 | Chlorthalidone Compositions And Methods | RAMOS LEWIS, JOSMALEN MILAGROS | 1621 | §103 | Non-Final OA | 40d | Pending | Mar 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial